Fig. 4From: Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trialTime to death by SOFA component score (ITT population). R-SOFA ≥ 2 (upper panel A), CV-SOFA ≥ 2 (middle panel B), R-SOFA ≥ 2 plus CV-SOFA ≥ 2 (bottom panel C). CV-SOFA cardiovascular SOFA component score, R-SOFA respiratory SOFA component score, SOFA Sequential Organ Failure AssessmentBack to article page